Senior Spatial Biomarker Scientist (IHC/mIF)
Bristol-Myers Squibb Co
Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Benefits offered by this job
Job summary
Bristol Myers Squibb is seeking a senior scientist to lead the strategy, development, and lifecycle management of tissue-based biomarker assays, including IHC, ISH, and digital pathology methods. You will partner with translational teams and manage external CROs to ensure high-quality data across early and late development stages.
The role requires advanced degrees in life sciences and a proven track record in assay validation, translational endpoints, and cross-functional collaboration within a
Qualifications
- Bachelor’s, Master’s or PhD in Life Sciences with extensive industry experience.
- PhD preferred with 2+ years in industry.
- Proven ability to manage CROs and external labs.
- Experience in tissue-based biomarker assay development.
- Strong analytical and data interpretation skills.
- Excellent written and verbal communication abilities.
Responsibilities
- Lead strategy and lifecycle management of tissue-based biomarker assays.
- Oversee assay transfer to CROs and external labs with quality oversight.
- Develop and implement translational biomarker strategies for clinical programs.
- Coordinate with translational scientists and internal labs for endpoints.
- Define QC criteria, acceptance specs, and data review processes.
- Drive innovation in spatial/digital pathology and emerging tech.
- Provide mastery in assay validation, robustness studies, and reporting.
Education
Tools
Job description
Bristol Myers Squibb is seeking a senior scientist to lead the strategy, development, and lifecycle management of tissue-based biomarker assays, including IHC, ISH, and digital pathology methods. You will partner with translational teams and manage external CROs to ensure high-quality data across early and late development stages.
The role requires advanced degrees in life sciences and a proven track record in assay validation, translational endpoints, and cross-functional collaboration within a
'/%3e%3cpath%20d='M101.744%2012.4726L102.894%2016.1947L99.0021%2013.2201L101.744%2012.4726ZM105.3%208.40937H100.488L99.0026%203.59473L97.5116%208.41047L92.7%208.40385L96.5965%2011.3834L95.1055%2016.1942L99.0021%2013.2196L101.408%2011.3834L105.3%208.40992V8.40937Z'%20fill='white'/%3e%3cdefs%3e%3clinearGradient%20id='paint0_linear_5593_1381'%20x1='90'%20y1='9.44471'%20x2='99'%20y2='9.44471'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%2300AD70'/%3e%3cstop%20offset='0.998594'%20stop-color='%2300B67A'/%3e%3cstop%20offset='1'%20stop-color='%23DCDCE6'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e){kind=small}
